JM Financial Ltd.
Avendus Capital Pvt. Ltd.
Motilal Oswal Investment Advisors Ltd.
Nomura Financial Advisory & Securities (India) Pvt. Ltd.

Symbiotec Pharmalab Ltd. is an Indian pharmaceutical and biotechnology company incorporated in 2002. Over more than 30 years of industry experience since starting in 1995 as a lab-scale operation, the company has evolved into a major industrial-scale platform that develops and manufactures active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products for domestic and global markets.

As of June 30, 2025, Symbiotec Pharmalab Ltd. operated two main industrial API facilities with a chemical synthesis capacity of 584.67 metric tonnes (MT) and a fermentation capacity of 300 kilolitres. Supported by certifications from global regulatory bodies—including the US FDA, EU-GMP, and Korea’s Ministry of Food and Drug Safety—the company focuses on quality compliance, research-driven manufacturing, and sustainable practices to supply the global healthcare and wellness sectors.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

*Market cap @upper band

• Global leadership in corticosteroid and steroidal hormone APIs.
• Long-standing relationships with domestic and international customers.
• Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
• Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
• Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.

The Company SYMBIOTEC PHARMALAB LIMITED IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

• Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company (Rs. 112.50 Cr.)
• General corporate purposes

At the upper band of IPO Rs. 988, the stock is valued at 56.81 P/E multiple. Hence, well-informed investors subscribe for medium to long term perspective.